Clinical-Stage Biotech Committed to Advancing Novel Therapies for Rare Endocrine Disorders

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Our team has extensive expertise in endocrinology and orphan drug development and our lead product candidate, SPR001, has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease. We are headquartered in San Francisco and closed a Series A financing of $20 million in 2016.

Or lead program, SPR001, is currently in Phase 2 clinical trials for CAH. For more information on CAH please visit our patient resources section. If you are a patient interested in learning more about our clinical trials and may be eligible to participate, please visit our clinical trials page.

Leadership+ Board of Directors + Investors +

Now Enrolling Patients for

Congenital Adrenal Hyperplasia Clinical Trials 2018

If you are an adult with a genetic diagnosis of classic Congenital Adrenal Hyperplasia, you may be eligible to participate in a Phase 2 clinical trial for a new therapy for CAH. To be notified when a site opens near you, sign up for our mailing list.

Our Phase 2 program has active sites in San Diego, CA, Orange, CA, Las Vegas, NV, Atlanta, GA, Indianapolis, IN, Minneapolis, MN, Melbourne, FL.

Learn More

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.